prikaz prve stranice dokumenta Combined Treatment with Host-Directed and Anticytomegaloviral Kinase Inhibitors: Mechanisms, Synergisms and Drug Resistance Barriers
  Preuzmi
PDF 2.11 MB
Znanstveni rad - Izvorni znanstveni rad
Combined Treatment with Host-Directed and Anticytomegaloviral Kinase Inhibitors: Mechanisms, Synergisms and Drug Resistance Barriers
Pharmaceutics, 15 (2023), 12; 2680. https://doi.org/10.3390/pharmaceutics15122680
Wild, Markus; Karner, Dubravka; Eickhoff, Jan; Wagner, Sabrina; Kicuntod, Jintawee; Chang, William; Barry, Peter; Jonjić, Stipan; Lenac Roviš, Tihana; Marschall, Manfred

Citirajte ovaj rad

Wild, M., Karner, D., Eickhoff, J., Wagner, S., Kicuntod, J., Chang, W. ... Marschall, M. (2023). Combined Treatment with Host-Directed and Anticytomegaloviral Kinase Inhibitors: Mechanisms, Synergisms and Drug Resistance Barriers. Pharmaceutics, 15. (12). doi: 10.3390/pharmaceutics15122680

Wild, Markus, et al. "Combined Treatment with Host-Directed and Anticytomegaloviral Kinase Inhibitors: Mechanisms, Synergisms and Drug Resistance Barriers." Pharmaceutics, vol. 15, br. 12, 2023. https://doi.org/10.3390/pharmaceutics15122680

Wild, Markus, Dubravka Karner, Jan Eickhoff, Sabrina Wagner, Jintawee Kicuntod, William Chang, Peter Barry, Stipan Jonjić, Tihana Lenac Roviš i Manfred Marschall. "Combined Treatment with Host-Directed and Anticytomegaloviral Kinase Inhibitors: Mechanisms, Synergisms and Drug Resistance Barriers." Pharmaceutics 15, br. 12 (2023). https://doi.org/10.3390/pharmaceutics15122680

Wild, M., et al. (2023) 'Combined Treatment with Host-Directed and Anticytomegaloviral Kinase Inhibitors: Mechanisms, Synergisms and Drug Resistance Barriers', Pharmaceutics, 15(12). doi: 10.3390/pharmaceutics15122680

Wild M, Karner D, Eickhoff J, Wagner S, Kicuntod J, Chang W, i sur.. Combined Treatment with Host-Directed and Anticytomegaloviral Kinase Inhibitors: Mechanisms, Synergisms and Drug Resistance Barriers. Pharmaceutics [Internet]. 27.11.2023. [pristupljeno 14.04.2024.];15(12). doi: 10.3390/pharmaceutics15122680

M. Wild, et al., "Combined Treatment with Host-Directed and Anticytomegaloviral Kinase Inhibitors: Mechanisms, Synergisms and Drug Resistance Barriers", Pharmaceutics, vol. 15, br. 12, Studeni 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:023389. [Citirano: 14.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:023389
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Combined Treatment with Host-Directed and Anticytomegaloviral Kinase Inhibitors: Mechanisms, Synergisms and Drug Resistance Barriers
AutorMarkus Wild
AutorDubravka Karner
AutorJan Eickhoff
AutorSabrina Wagner
AutorJintawee Kicuntod
AutorWilliam Chang
AutorPeter Barry
AutorStipan Jonjić
AutorTihana Lenac Roviš
AutorManfred Marschall
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Centar za proteomiku)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
Despite the availability of currently approved antiviral drugs, infections with human cytomegalovirus (HCMV) still cause clinically challenging, sometimes life-threatening situations. There is an urgent need for enhanced anti-HCMV drugs that offer improved efficacy, reduced dosages and options for long-term treatment without risk of the development of viral drug resistance. Recently, we reported the pronounced anti-HCMV efficacy of pharmacological inhibitors of cyclin-dependent kinases (CDKs), in particular, the potential of utilizing drug synergies upon combination treatment with inhibitors of host CDKs and the viral CDK-like kinase pUL97 (vCDK/pUL97). Here, we expand this finding by further assessing the in vitro synergistic antiviral interaction between vCDK and CDK inhibitors towards HCMV as well as non-human cytomegaloviruses. An extension of this synergy approach was achieved in vivo by using the recombinant MCMV-UL97/mouse model, confirming the high potential of combination treatment with the clinically approved vCDK inhibitor maribavir (MBV) and the developmental CDK7 inhibitor LDC4297. Moreover, mechanistic aspects of this synergistic drug combination were illustrated on the levels of intracellular viral protein transport and viral genome replication. The analysis of viral drug resistance did not reveal resistance formation in the case of MBV + LDC4297 combination treatment. Spanning various investigational levels, these new results strongly support our concept, employing the great potential of anti-HCMV synergistic drug treatment.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaPharmaceutics
Brojčani podacivol. 15, br. 12, 2680
e-ISSN1999-4923
DOIhttps://doi.org/10.3390/pharmaceutics15122680
URN:NBNurn:nbn:hr:184:023389
Datum objave publikacije2023-11-27
URL dokumentahttps://www.mdpi.com/1999-4923/15/12/2680
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2023-11-29 09:29:22